Why the study?
Do different beta-blockers (carvedilol, metoprolol, propranolol) or bunazosin attenuate left ventricular remodeling in rats with coronary stenosis or permanent coronary occlusion?
Do different beta-blockers (carvedilol, metoprolol, propranolol) or bunazosin attenuate left ventricular remodeling in rats with coronary stenosis or permanent coronary occlusion?
Carvedilol provides superior cardioprotection and attenuation of left ventricular remodeling compared to other beta-blockers in a rat model of ischemic but viable myocardium.
Answers are grounded in this paper and cite their sources.
May favor carvedilol for LV remodeling in ischemic models; leaves open clinical relevance and comparative efficacy in patients.
BACKGROUND: Although carvedilol attenuates left ventricular (LV) remodeling in coronary occlusion-reperfusion, it is not known whether it attenuates ischemic LV remodeling because of coronary stenosis (CS) or permanent coronary occlusion (CO). METHODS AND RESULTS: We administered a vehicle, carvedilol, propranolol (2, 10, and 30 mg/kg per day, each), metoprolol (6, 30, and 90 mg/kg per day), or bunazosin (0.2 and 1 mg/kg per day), orally for 12 weeks to a total of 608 rats with CS or CO. In these groups and the sham (n=40), we assessed LV function by echocardiography, CS severity, myocardial blood flow and coronary flow reserve, serum ascorbyl free radical, and vitamin C. Both CS and CO increased LV end-diastolic and end-systolic diameters and decreased ejection fraction. The 4 agents failed to attenuate LV remodeling caused by CO. In contrast, the 3 beta-blockers attenuated (P<0.01) or tended to attenuate the increase in LV end-diastolic diameters caused by CS. With similar blood pressure and heart rate lowering by 3 beta-blockers, carvedilol additionally attenuated the increase in end-systolic diameters and improved ejection fraction. The CS reduced myocardial blood flow and coronary flow reserve, which was reversed by carvedilol without modifying the CS severity. Among the 4 agents, only carvedilol decreased ascorbyl free radical and increased vitamin C. CONCLUSIONS: The effects of beta blockade on ischemic cardiac dysfunction seem to depend on the different properties of the beta-blockers and the doses used. Among the beta-blockers tested, carvedilol provided potent cardioprotection for compromised ischemic but viable myocardium rather than for infarcted myocardium.
No takes yet. Share an insight, caveat, or question.
Yaoita et al. (2002) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: